Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • DOT1L Inhibition with EPZ5676 Attenuates Renal Fibrosis

    2026-04-12

    DOT1L Inhibition with EPZ5676 Attenuates Renal Fibrosis

    Study Background and Research Question

    Chronic kidney disease (CKD) remains a global health burden, affecting 10-15% of the population and frequently progressing to end-stage renal disease (ESRD) with limited treatment options other than dialysis or transplantation. A central pathological feature of CKD progression is renal fibrosis, characterized by activation of renal interstitial fibroblasts and excessive extracellular matrix (ECM) deposition, which leads to irreversible organ dysfunction. While the importance of epigenetic regulation in tumorigenesis is well established, its role in tissue fibrosis is less characterized. The histone methyltransferase DOT1L, known for catalyzing methylation at lysine 79 of histone H3 (H3K79), has been implicated in leukemogenesis, particularly in MLL-rearranged leukemia, but its involvement in fibrosis had not been fully explored. The central research question addressed by Liu et al. (FASEB J., 2019) is whether inhibition of DOT1L-mediated H3K79 methylation can attenuate renal fibrosis by interfering with key cellular processes such as fibroblast activation and epithelial-mesenchymal transition (EMT).

    Key Innovation from the Reference Study

    The primary innovation of this study is the demonstration that selective inhibition of DOT1L with EPZ5676—a molecule previously validated in oncology—can significantly reduce renal fibrosis in vivo. This provides mechanistic evidence directly linking DOT1L activity and H3K79 methylation with the fibrotic cascade in the kidney, particularly by disrupting both renal fibroblast activation and EMT. This work expands the potential application of DOT1L inhibitors beyond hematology, identifying DOT1L as a promising epigenetic target for organ fibrosis. The use of EPZ5676, a highly selective DOT1L inhibitor with nanomolar potency, enabled the authors to dissect the epigenetic control of fibrosis with unprecedented specificity [source_type: paper][source_link: https://doi.org/10.1096/fj.201801861R].

    Methods and Experimental Design Insights

    Liu et al. employed a combination of in vivo and in vitro approaches to interrogate the role of DOT1L in renal fibrosis. In a murine model of unilateral ureteral obstruction (UUO)—a well-characterized model of progressive renal fibrosis—the authors observed increased DOT1L expression and H3K79 dimethylation in renal tubular epithelial cells and myofibroblasts following injury. Mice were treated with EPZ5676 to assess the effect of DOT1L inhibition on fibrogenesis. Parallel in vitro studies used both EPZ5676 and DOT1L-targeted small interfering RNA (siRNA) to inhibit DOT1L activity in cultured renal fibroblasts and proximal tubular epithelial cells exposed to profibrotic stimuli such as TGF-β1 and serum.

    Key endpoints included immunohistochemistry and western blotting for markers of fibroblast activation (e.g., α-smooth muscle actin), ECM protein deposition, H3K79 methylation status, and expression of EMT-associated transcription factors (Snail, Twist, Notch1). The activation state of multiple profibrotic signaling pathways was also interrogated, including Smad3, EGFR, PDGFR, STAT3, AKT, and NF-κB, alongside measurement of renoprotective factors (Klotho, Smad7, PTEN).

    Protocol Parameters

    • assay | EPZ5676 dosing in UUO mouse model | 70 mg/kg/day via continuous infusion | Murine renal fibrosis attenuation | Dose based on prior preclinical oncology studies | paper [source_link: https://doi.org/10.1096/fj.201801861R]
    • assay | DOT1L inhibitor (EPZ5676) IC50 | 0.8 nM (DOT1L enzyme) | Selectivity for DOT1L vs. other methyltransferases | Confirmed in biochemical inhibition assays | product_spec [source_link: https://www.apexbt.com/epz5676.html]
    • assay | In vitro H3K79 methylation inhibition | 10-100 nM EPZ5676 | Effective in renal fibroblasts and epithelial cells | Doses reflect nanomolar potency for pathway modulation | paper [source_link: https://doi.org/10.1096/fj.201801861R]
    • assay | EMT marker suppression (Snail, Twist, Notch1) | >50% reduction with EPZ5676 (10–100 nM) | In cultured renal cells after TGF-β1 stimulation | Demonstrates EMT pathway dependency on DOT1L activity | paper [source_link: https://doi.org/10.1096/fj.201801861R]
    • assay | Acute leukemia cell line cytotoxicity | IC50 = 3.5 nM in MV4-11 cells | Benchmark for EPZ5676 potency in MLL-fusion leukemia | Oncology relevance, not directly assessed in kidney models | product_spec [source_link: https://www.apexbt.com/epz5676.html]

    Core Findings and Why They Matter

    The study provides compelling evidence that DOT1L-mediated H3K79 methylation is a pivotal epigenetic event in renal fibrogenesis. Injury-induced upregulation of DOT1L and H3K79me2 was observed in both tubule epithelial cells and myofibroblasts. Pharmacological inhibition of DOT1L with EPZ5676 significantly attenuated histological and molecular markers of renal fibrosis in the UUO mouse model. In vitro, both EPZ5676 and DOT1L siRNA suppressed fibroblast activation and EMT in response to TGF-β1 and serum, as evidenced by reduced α-SMA and ECM protein expression [source_type: paper][source_link: https://doi.org/10.1096/fj.201801861R].

    Mechanistically, DOT1L inhibition led to downregulation of key EMT and profibrotic transcription factors (Snail, Twist, Notch1) and inactivation of multiple signaling nodes (Smad3, EGFR, PDGFR, STAT3, AKT, NF-κB). Notably, EPZ5676 treatment restored levels of renoprotective proteins Klotho and Smad7, and increased PTEN expression, suggesting that targeting DOT1L not only impedes pro-fibrotic pathways but also supports kidney homeostasis. These findings establish DOT1L as an essential regulator of the fibrotic response and provide a foundation for exploring DOT1L inhibitors in CKD-related fibrosis [source_type: paper][source_link: https://doi.org/10.1096/fj.201801861R].

    Comparison with Existing Internal Articles

    Most internal literature on EPZ5676 (Pelubiprofencas, Histone-H2A, Glycoprotein-B) focuses on its application in leukemia, particularly MLL-rearranged subtypes, where its selectivity and nanomolar potency allow for robust H3K79 methylation inhibition and antiproliferative activity in acute leukemia cell lines [source_type: workflow_recommendation][source_link: https://pelubiprofencas.com/index.php?g=Wap&m=Article&a=detail&id=18]. However, these reviews do not address tissue fibrosis or the broader implications of DOT1L inhibition in non-malignant disease. The present study is the first to robustly link DOT1L inhibition with attenuation of renal fibrosis, thereby broadening the therapeutic and research relevance of DOT1L-targeted strategies beyond oncology. This cross-domain application is supported by direct evidence in the reference paper and provides a rationale for researchers in nephrology and fibrosis fields to consider epigenetic modulators as experimental tools.

    Limitations and Transferability

    While the use of EPZ5676 in the UUO mouse model demonstrates clear anti-fibrotic effects, several limitations should be considered. First, the study relies primarily on preclinical models; translation to human CKD remains to be rigorously tested. Second, the dosing regimen for EPZ5676 in fibrosis may differ from its established use in oncology, and long-term safety data in non-oncologic contexts are lacking. The specificity of DOT1L inhibition is high, but potential off-target effects in complex tissues should be further investigated. Additionally, while the reduction in profibrotic signaling is compelling, the study does not address potential compensatory epigenetic mechanisms that might arise with chronic DOT1L inhibition. Transferability to other organ fibrosis models or human disease requires further validation.

    Why this cross-domain matters, maturity, and limitations

    This research exemplifies a successful bridge between oncology-derived epigenetic tools and organ fibrosis, an area of significant unmet need. The direct evidence for DOT1L involvement in renal fibrogenesis and the robust anti-fibrotic effect of EPZ5676 support further exploration of DOT1L inhibitors in kidney disease. However, as the findings are primarily preclinical, clinical translation requires careful dose optimization, safety assessment, and consideration of long-term epigenetic effects. No data yet support use in human CKD or in fibrosis of other organs; thus, the cross-domain application should be considered investigational at present [source_type: paper][source_link: https://doi.org/10.1096/fj.201801861R].

    Research Support Resources

    Researchers aiming to model or interrogate the role of DOT1L in renal fibrosis, EMT, or related epigenetic mechanisms may utilize EPZ5676 (SKU A4166), a highly selective DOT1L inhibitor validated in both oncology and fibrosis models. EPZ5676 is available from APExBIO and offers a robust reagent for histone methyltransferase inhibition assays and studies of H3K79 methylation dynamics. For optimal results, reference dosing protocols and solvent recommendations should be consulted as per product specifications [source_type: product_spec][source_link: https://www.apexbt.com/epz5676.html].